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Abstract
Background: Mesenchymal stromal cells isolated from bone marrow (MSC) represent an attractive source of adult
stem cells for regenerative medicine. However, thorough research is required into their clinical application safety
issues concerning a risk of potential neoplastic degeneration in a process of MSC propagation in cell culture for
therapeutic applications. Expansion protocols could preselect MSC with elevated levels of growth-promoting
transcription factors with oncogenic potential, such as c-MYC. We addressed the question whether c-MYC expression
affects the growth and differentiation potential of human MSC upon extensive passaging in cell culture and assessed a
risk of tumorigenic transformation caused by MSC overexpressing c-MYC in vivo.
Methods: MSC were subjected to retroviral transduction to induce expression of c-MYC, or GFP, as a control. Cells were
expanded, and effects of c-MYC overexpression on osteogenesis, adipogenesis, and chondrogenesis were monitored.
Ectopic bone formation properties were tested in SCID mice. A potential risk of tumorigenesis imposed by MSC with
c-MYC overexpression was evaluated.
Results: C-MYC levels accumulated during ex vivo passaging, and overexpression enabled the transformed
MSC to significantly overgrow competing control cells in culture. C-MYC-MSC acquired enhanced biological
functions of c-MYC: its increased DNA-binding activity, elevated expression of the c-MYC-binding partner MAX,
and induction of antagonists P19ARF/P16INK4A. Overexpression of c-MYC stimulated MSC proliferation and
reduced osteogenic, adipogenic, and chondrogenic differentiation. Surprisingly, c-MYC overexpression also
caused an increased COL10A1/COL2A1 expression ratio upon chondrogenesis, suggesting a role in hypertrophic
degeneration. However, the in vivo ectopic bone formation ability of c-MYC-transduced MSC remained comparable to
control GFP-MSC. There was no indication of tumor growth in any tissue after transplantation of c-MYC-MSC in mice.
Conclusions: C-MYC expression promoted high proliferation rates of MSC, attenuated but not abrogated their
differentiation capacity, and did not immediately lead to tumor formation in the tested in vivo mouse model.
However, upregulation of MYC antagonists P19ARF/P16INK4A promoting apoptosis and senescence, as well as
an observed shift towards a hypertrophic collagen phenotype and cartilage degeneration, point to lack of
safety for clinical application of MSC that were manipulated to overexpress c-MYC for their better expansion.
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Background
While embryonic stem (ES) cells represent pluripotent
cells with a capacity to form any cell type and tissue in
human body during embryonic development, adult stem
cells serve for cell replenishment in case of injury or loss
due to limited lifespan of terminally differentiated cells.
An important class of adult stem cells are mesenchymal
stromal cells (MSC) that have been found in bone mar-
row and many other postnatal tissues and shown to de-
velop into the cells of various mesenchymal tissues such
as fat, cartilage, or bone [1, 2]. MSC from bone marrow
and adipose tissue are an attractive cell source for regen-
erative medicine due to their high proliferation capacity
[3], multi-lineage differentiation potential [4], and the
trophic support of surrounding tissues through secretion
of bioactive factors [5]. Therefore, MSC are not only ap-
plied for treatment of degenerative musculoskeletal dis-
eases [6, 7], but also for other stem cell-based therapies,
such as steroid-refractory graft-versus-host disease
(GvHD) [8], vascular diseases [9], neurological disorders
[10], and others [11].
However, only limited numbers of bone marrow-de-
rived MSC, which also decline with age of a donor [12],
could be obtained from a patient by painful and invasive
isolation techniques. Thus, for successful outcome that
requires large cell quantities for many clinical applica-
tions, MSC need to be expanded in a long-term cell cul-
ture. This, however, raises concerns about clinical safety
of MSC that have undergone ex vivo expansion. Al-
though their ability to evade immune surveillance [13]
and reported immunosuppressive properties [14] make
MSC an ideal tool for clinical applications [15], long cul-
ture expansion could impact these characteristics [16].
The major concern for the therapeutic application of
MSC is the risk of possible tumorigenic transformation.
It has been demonstrated that, upon prolonged ex vivo
expansion, MSC may undergo cellular senescence [3,
17]. Even though no apparent accumulation of chromo-
somal aberrations or genetic mutations have been re-
ported for MSC that undergone senescence due to
prolonged ex vivo passaging [3, 18], epigenetic changes
associated with senescence, differentiation and alteration
of immune response of these cells have been described
[19, 20]. The question whether MSC could undergo ma-
lignant transformation themselves or induce tumor
growth remains controversial, as there have been reports
ruling out a possibility of malignant transformation of
MSC [21–25], as well as studies demonstrating that
these concerns cannot be dismissed [26]. In respect of
tumor pathogenesis, MSC could either promote and as-
sist cancer cell growth [27] or undergo neoplastic trans-
formation themselves [28–30]. In October 2011, the Cell
Products Working Party (CPWP) arranged a meeting be-
tween the experts working in the MSC research field to
discuss contradictory finding on this subject and de-
fine certain standards in MSC cultivation and quality
tests before their clinical application. It has been con-
cluded that more clinical observations supported by
animal studies would be necessary to address the
existing concerns about MSC tumorigenicity in clin-
ical applications [31].
Exposure to the growth factors present in culture media
for ex vivo expansion could lead to activation of oncogenic
transcription factors triggering neoplastic transformation
of the MSC. Available protocols designed to achieve high
proliferation rates may condition for selection of those
MSC that overexpress the growth-promoting factors. It
has been shown that serum growth factors used in com-
mon ex vivo expansion protocols can increase c-MYC ex-
pression levels and consequently stimulate higher cell
growth rates [32]. Growth factors, such as bFGF (basic
fibroblast growth factor) [33], PDGF (platelet-derived
growth factor) [34], and various BMPs (bone morpho-
genetic proteins) [35], have been demonstrated to induce
MYC expression. Additionally, in case of murine bone
marrow mesenchymal stem cells (BMSC), their ex vivo ex-
pansion resulted in higher expression of c-MYC in com-
parison to the initial cell population [36]. Furthermore,
bone marrow MSC-conditioned medium has been dem-
onstrated to promote cancer development via upregula-
tion of c-MYC [37]. Therefore, c-MYC expression
provides and supports high proliferation rates of MSC
which are necessary for their expansion for many thera-
peutics applications.
However, c-MYC plays not only an important role in cell
proliferation, but also is involved in other multiple func-
tions, such as cell differentiation, apoptosis, cell cycle pro-
gression, and cellular transformation leading to tumor
pathogenesis. The MYC (MYC Proto-Oncogene, BHLH
Transcription Factor, other names are C-MYC or V-MYC)
family of proto-oncogenes consists of c-MYC that is found
to be amplified in many types of cancer, and other para-
logs expressed in specialized cases, such as MYCN (this
gene amplification has been detected only in neuroblast-
oma [38]), and MYCL (has been found in lung carcinoma
[39]). All MYC proteins are transcription factors with
basic helix loop helix motifs that are required for heterodi-
merization with MAX (MYC-associated protein X). The
MYC/MAX heterodimer binds to E-box DNA recognition
elements in the promotor region of target genes causing
activation of transcription. In this complex, MAX
protein determines E-box specificity, and MYC works
as an activator. MAX can additionally form heterodi-
mers with the related proteins of the MAD/MNF
family, which in turn antagonize the activating effect
of MYC/MAX on the same targets. In many cases,
the antagonism between MYC and MAD in vivo can
be related to a switch of cells from proliferation
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(MYC/MAX activation) to differentiation (MAD/MAX
repression) [40]. Thus, MAD proteins play an import-
ant role in antagonizing MYC function, which could
also be relevant in MSC.
Another antagonist of MYC is the tumor suppressor
P19ARF that can block activating functions of MYC by
direct binding, without affecting its expression [41].
P19ARF and P16INK4A tumor suppressor genes are both
products of a common gene CDKN2A (cyclin-dependent
kinase inhibitor 2A). They are mediators of cellular senes-
cence and apoptosis and have been shown to antagonize
aberrant growth signaling caused by gain-of-function of
MYC and RAS proteins [42], in particular, to protect cells
from neoplastic transformation. Also, in human MSC,
P16INK4A expression has been shown to correlate with
replicative senescence [43]. Thus, the correlations between
MYC and P19ARF/P16INK4A could be a key switch-
ing point in the transition from stem cell function to
senescence and concomitant loss of stem cell proper-
ties of MSC.
Deregulated expression of c-MYC has been implicated
in progression of many types of cancer. The involvement
of MYC for the emergence of carcinogenesis is well docu-
mented [44–47], as well as its crucial role in the regulation
of pluripotency and self-renewal capacity of murine stem
cells: ES, neural (NSC) and hematopoietic (HSC), by using
various transgenic mouse models [48]. It is important to
mention that MYC overexpression itself, without other
mutations, is not sufficient for tumorigenic transform-
ation. For example, it has been demonstrated that only 1
in 10 of transgenic mice that have c-Myc gain-of-function
could develop a tumor, with an average latency period of
200 days. However, when overexpression of c-Myc in this
animal model was combined with gain-of-function of an-
other oncogene, Her2 (other name Erbb2: erb-b2 receptor
tyrosine kinase 2), tumor penetrance reached 100% [49].
Similar effects have been demonstrated for the cases when
c-MYC overexpression was combined with a loss or silen-
cing of tumor suppressor genes, e.g., CDKN2A locus [50],
or with RB (Retinoblastoma) protein inactivation [51],
when these led to transformation of MSC and acquisition
of a malignant osteosarcoma phenotype.
In contrary to murine stem cells, there are limited data
on a role of MYC in adult human stem cell populations,
such as NSC, HSC, and MSC. This question has been
investigated in more details only for human epidermal
stem cells [52]. Surprisingly, in these cells, MYC rather
stimulated cell differentiation than their proliferation.
This implies that effects caused by MYC expression
could be context-dependent and more complex than a
simple on/off mechanism. For example, the observed
triggering of epidermal stem cell differentiation by MYC
could be interpreted as a cell safety mechanism against
the oncogenic potential of high MYC levels [53].
There are only very few reports about a possible cor-
relation between the c-MYC protein levels and the
growth potential of human MSC [54, 55]. Namely, it has
been shown that in human adipose tissue-derived stem
cells, c-MYC expression could be enhanced upon ex vivo
expansion, and this correlated with increased prolifera-
tion rates of adipose tissue mesenchymal stromal cells
(ASC) [32]. There are no other direct data on a possible
impact of high MYC expression on growth, differenti-
ation, and tumorigenic potential of human bone
marrow-derived MSC. It yet remains to be assessed how
MSC ex vivo expansion would affect their stem cell-like
properties and whether these cells would impose a safety
risk due to increased tumorigenic potential that might
hinder their therapeutic application.
The aim of this study was to provide data on a role of
c-MYC expression during extensive ex vivo expansion of
bone marrow-derived MSC and examine whether
c-MYC overexpression impacts proliferation and differ-
entiation capacities of these cells. We also assayed how
elevated expression of c-MYC in MSC would affect their
bone tissue formation ability in vivo and whether it
might enforce a potential risk of tumor formation in re-
cipients, to address the concerns about consequent im-
plications for therapeutic compatibility of these cells.
Methods
Isolation and expansion of MSC
The study with application human donor samples was ap-
proved by the local ethics committee (Medical Faculty of
the University of Heidelberg), and an informed consent
was obtained from all the patients participating in the
study, according to the 1964 Declaration of Helsinki,
updated in 2000. Only cells from HIV-, HBV-, and
HCV-negative donors were used. Human ASC were ob-
tained from liposuction aspirates of a human donor, and
isolated, as described before [56]. Articular chondrocytes
were isolated from articular cartilage resected from tibia
plateaus of a patient undergoing total knee replacement, as
described [57]. Bone marrow MSC were isolated from fresh
bone marrow aspirates of human donors (n = 20) that had
undergone a total hip replacement procedure. MSC popu-
lation was isolated, as described before [58]. In brief, cells
were fractionated by Ficoll-Paque™ density gradient centri-
fugation. The mononuclear cell fraction was seeded at a
density of 1.25 × 105cells/ cm2 in 0.1% gelatin-coated flasks
and maintained at 37 °C in humidified atmosphere with 6%
CO2. Next day, cells were washed with phosphate-buffered
saline (PBS), to remove non-adherent cells, and expanded
in ES medium composed of DMEM with high glucose,
12.5% FCS, 2mM L-glutamine, 50 μM β-mercaptoethanol,
1% non-essential amino acids (all from Gibco, Invitrogen,
Karlsruhe, Germany), 100 units/ml penicillin, 100 μg/ml
streptomycin, and 4 ng/ml basic fibroblast growth factor
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(bFGF) (Active Bioscience, Hamburg, Germany). When in-
dicated, bFGF was omitted from ES media for the duration
of MSC expansion. For osteogenic or adipogenic differenti-
ation, expanded MSC were harvested at passages 4, 6, 8,
and 10 with trypsin/ethylenediaminetetraacetic acid
(EDTA). Cells were seeded at densities 3.5 × 105 cells per
well into a 24-well cell culture plate with corresponding
differentiation media.
Osteogenic differentiation of MSC
After expansion, MSC were subjected to osteogenic-in-
duction medium consisting of high-glucose DMEM, 10%
FCS (Biochrom, Berlin, Germany), 0.1 μm dexametha-
sone, 0.17 mM ascorbic acid 2-phosphate, 10 mM
β-glycerophosphate (all from Sigma, Deisenhofen,
Germany), 100 units/ml penicillin, and 100 μg/ml
streptomycin. Cells were cultured for 3 weeks with
medium changes twice per week. To monitor osteogenic
differentiation, cells were stained with 0.5% Alizarin Red
S (Chroma, Münster, Germany), to detect calcium
deposition. Next, they were treated with 10%
cetylpyridiniumchloride-solution (Sigma, Deisenhofen,
Germany) to extract calcium-bound dye, and calcium
content was measured using spectrophotometry at 570
nm. The values were normalized to the total protein
content in cell lysates using Bradford Reagent (Sigma,
Deisenhofen, Germany).
Adipogenic differentiation of BMSC
After expansion, MSC were subjected to adipogenic in-
duction medium consisting of DMEM high glucose, 10%
FCS, 1 μm dexamethasone, 0.2 mM indomethacine, 0.5
mM isobutylmethylexanthine (all Sigma, Deisenhofen,
Germany), 0.01 mg/ml insulin (Sanofi-Aventis, Frankfurt,
Germany), 100 units/ml penicillin, and 100 μg/ml
streptomycin. Cells were cultured for 3 weeks with
medium changed twice per week. To monitor adipogen-
esis, cells were fixed with 4% paraformaldehyde and
stained with 0.3% Oil Red O solution (Chroma, Münster,
Germany). Dye was re-extracted from vacuoles by 60%
isopropanol and quantified by measuring its optical
density at 490 nm.
Chondrogenic differentiation of MSC
For chondrogenic differentiation, MSC were harvested
after passage 4, and 5 × 105 of cells were collected in
1.5-ml Eppendorf tubes by centrifugation (600g, 10min),
and subjected to high-density 3D culture in chondrogenic
induction medium containing high-glucose DMEM sup-
plemented with 0.1 μM dexamethasone, 0.17mM ascorbic
acid 2-phosphate, 5 μg/ml transferrin, 5 ng/ml selenous
acid, 1 mM sodium pyruvate, 0.35mM proline, 1.25mg/
ml BSA, 100 units/ml penicillin, 100 μg/ml streptomycin,
5 μg/ml insulin (Sanofi-Aventis, Frankfurt, Germany), and
10 ng/ml TGF-β1 (Peprotech, Hamburg, Germany). Pel-
lets were cultured up to 6 weeks, with medium changed
three times per week. To monitor chondrogenic differenti-
ation, proteoglycan deposition was measured. For this,
pellets were fixed with 4% paraformaldehyde, embedded
in paraffin, and 5-μm sections were cut and stained with
Safranin O solution (Safranin T Fluka Nr. 84,120, Fluka,
Monte Carlo) and Fast Green (Chroma 1A 304, Chroma,
Münster, Germany).
Quantification of proteoglycan content (DMMB assay)
Proteoglycan content in cartilaginous tissue was mea-
sured by DMMB (dimethyl-methylene Blue) assay. For
this, pellets (n = 2 per donor) were harvested at day 42
of the chondrogenic induction, washed with PBS, and
digested overnight in 1 ml of lysis buffer containing 50
mM Tris, pH 8.0, and 1 mM CaCl2 with 500 μg/ml Pro-
teinase K (Roche, Mannheim, Germany) at 60 °C. Thirty
microliters of digested pellets were mixed with 200 μl of
DMMB solution (38 μM dimethyl-methylene blue,
Sigma, 40 mM glycine, 40 mM NaCl), and proteoglycan
content was measured by spectrophotometry at 540 nm,
and quantified using a standard curve built using chon-
droitin sulphate as a standard. The values were normal-
ized to DNA amount in lysed cells measured with
Quanti-iT PicoGreen dsDNA kit (Invitrogen, Eugene,
USA). For this, 20 μl of the digested pellet sample were
mixed with 80 μl TE buffer (200 mM Tris HCl, 20 mM
EDTA) and PicoGreen solution, and fluorescence in
samples was measured at 485/535 nm.
Retroviral vector cloning and retrovirus production
For retroviral expression of MYC, a 1320 bp fragment en-
coding human v-myc myelocytomatosis viral oncogene
homolog (MYC) was sub-cloned from pMXs-hc-MYC
plasmid (a gift from Shinya Yamanaka, Addgene plasmid #
17220 [59]) into the NcoI site of the retroviral vector
pBullet [60], after blunt-ending reaction with Klenow en-
zyme. The similar approach was taken for cloning of a
control construct expressing eGFP (enhanced green fluor-
escent protein). The resulting vectors were designated as
pBullet-cMYC and pBullet-eGFP. For retrovirus produc-
tion, HEK293T cells were transfected with retroviral vec-
tors (either with pBullet-cMYC or pBullet-eGFP, together
with helper plasmids pHit60 and pHCMV-G, as described
before [61]) using calcium phosphate transfection system
(Life Technologies, Groningen, The Netherlands), accord-
ing to the manufacturer’s protocol. In brief, 2 × 106 cells
were seeded on 10-cm dishes and transfected the next day
using 10 μg of pBullet-cMYC or pBullet-eGFP. After 18 h,
culture medium was discarded and replaced with 5ml of
fresh supplement. The next day, medium containing
retrovirus was harvested, filtered through a 0.45 μm filter,
and used for retroviral transduction. Retroviruses used for
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the subsequent transduction experiments were estimated
to be at MOI (multiplicity of infection) = 5.
Retroviral transduction of MSC
After isolation, MSC were passaged 1 day before retro-
virus transduction experiment. For this, 450 μl of virus
supernatant, 550 μl ES medium, and 8 μg/ml polybrene
were mixed and added to culture medium of MSC. Two
hours later, additional 4 ml of ES medium were added,
and media was replaced 48 h later. Cells were expanded
for up to 15 passages at a seeding density of 4000 cells/
cm2. For differentiation experiments, MSC were trans-
ferred to corresponding differentiation media at passage
4, 6, 8, or 10. At every passage, cell numbers and culture
time were noted in order to record a cumulative expan-
sion time cell numbers.
RNA extraction and quantitative mRNA expression
analysis (qRT-PCR)
Total RNA was isolated from pellets using a standard
guanidiniumthiocyanate/phenol extraction protocol (peq-
GOLD TriFastTM; Peqlab, Erlangen, Germany). Polyade-
nylated mRNA was isolated using oligo d(T)-coupled
magnetic beads (Dynabeads, Dynal, Invitrogen GmbH,
Karlsruhe, Germany) according to the manufacturer’s in-
struction. Twenty nanograms of mRNA was used for the
first strand cDNA synthesis with reverse transcriptase
(Omniscript®, Qiagen, Hilden, Germany) and oligo-d(T)
primers. Quantitative reversed transcriptase PCR
(qRT-PCR) was performed using SYBR green I mix
(Thermo Scientific, Rockford, USA) and gene-specific
primers (Additional file 1: Table S1) with Stratagen-
eMx3000P (Agilent Technologies, Böblingen, Germany).
mRNA expression was calculated using 2−ΔΔCT method
[62], with β-actin (ACTB) used as a reference gene.
Western blot (WB) analysis
Cells from pellets were lysed in lysis buffer containing
50mM Tris 7.4, 150 mM NaCl, 1% Triton X-100 for 5
min on ice. Lysates were cleared by centrifugation and
proteins were resolved by SDS-PAGE, blotted onto a
nitrocellulose membrane, and analyzed by Western blot-
ting (WB). The following antibodies were used: c-MYC
(clone 9E10, SC-40, Santa Cruz) and β-actin (AC-15,
GeneTex, USA) was used as reference protein.
MYC DNA-binding activity ELISA assay
DNA-binding activity of c-MYC was measured with
TransAM c-Myc Transcription Factor ELISA Assay Kit
(Active Motif, Inc., Carlsbad, USA), according to the
manufacturer’s instructions. In brief, 2.5 μg of nuclear
extracts isolated from cell pellets with Nuclear Extract
Kit (Active Motif, Inc., Carlsbad, USA) were incubated
with a synthetic oligonucleotide containing the c-MYC
consensus sequence. After incubation, DNA-bound
c-MYC was detected with c-MYC antibody and HRP-
conjugated secondary antibody by a colorimetric assay,
and quantified using a standard curve. Nuclear extract
from Jurkat cells, as well as positive and negative con-
trols for binding with c-MYC (oligonucleotides contain-
ing either mutated or wild-type c-MYC-binding
sequence, respectively, in competition with the tested
samples) were used as assay controls (data not shown).
Animal experiments
Animal care and all animal experiments were performed
according to the national guidelines, approved by the re-
sponsible national authority, the local Governmental
Committee for Animal Experimentation (Regierungspräsi-
dium Karlsruhe, Germany), and carried out accordingly.
Preparation of β-TCP constructs
Beta-tricalcium phosphate hydrate (β-TCP) constructs
[63] were prepared as described before [56]. In brief,
β-TCP grains (10 mg, particle size 0.25–1 μm,
Sigma-Aldrich Chemie GmbH, Steinheim, Germany)
were autoclaved in 30 μl phosphate-buffered saline
(PBS), to preserve hydrophilic properties. After complete
removal of PBS, 1 × 106 MSC collected after passage 2
were resuspended in 10 μl of fibrinogen (Tisseel, Baxter,
Unterschleissheim, Germany) diluted 1:15 in PBS and
added to the β-TCP, together with a short (1.5–2 cm)
surgical thread inserted in a tube, then incubated for 10
min. A cell-free β-TCP/fibrinogen and biomaterial-free
cells/fibrinogen suspensions were prepared as controls.
Next, 10 μl of 1:50 diluted thrombin (Tisseel) were
added, to allow polymerization into a β-TCP construct
at room temperature for 5 min. After preparation,
β-TCP constructs were soaked in 1 ml of PBS dislodged
from a tube and implanted into host animals.
In vivo ectopic bone formation
For ectopic bone formation experiments, female SCID
mice, n = 8 (CB17/Icr-Prkdcscid/IcrIcoCrl, Charles River,
Sulzfeld, Germany) aged at 10–12 weeks were used as
hosts. Immediately after preparation, β-TCP constructs
were implanted surgically into skin pockets (5 mm × 5
mm) of host animals under general anesthesia (120mg/
kg ketamine (Ketavet®, 100 mg/ml, Pfizer) and 0.5 mg/kg
medetomidine hydrochloride (Domitor®, 1 mg/ml, Pfi-
zer)). Up to four constructs per animal, comprising a
combination of different β-TCP constructs (c-MYC-
transduced, GFP-transduced, or control MCS constructs,
along with control cell-free, and biomaterial-free con-
structs), were implanted in anterior or posterior parts at
a dorsal side of a mouse. After the transplantation, ani-
mals were sacrificed at day 42 via CO2; the implants
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were excised and subjected to histological analyses and
in situ hybridization assay.
Histology
Histological evaluation of expanded MSC after differenti-
ation and explanted β-TCP constructs was performed, as
described [56]. In brief, β-TCP constructs or MSC pellets
were fixed in 4% paraformaldehyde for 24 h. β-TCP con-
structs were additionally decalcified in ethylenediamine-
tetraacetic acid (EDTA) for 4–5 days. Next, specimens
were dehydrated using a graded alcohol series, embedded
in paraffin, sectioned into 5-μm slices, and either stained
with hematoxylin-eosin (HE), according to a standard
protocol, or subjected to in situ hybridization assay. For
histomorphometrical analysis, to quantify a total area of
bone tissue, 48–54 sections were analyzed for each treat-
ment group using ImageJ software.
In situ hybridization assay
To discriminate cells of human or murine origin, in situ
hybridization was performed, as described before [64].
In brief, after fixation and cutting, thin sections were
subjected to hybridization with DIG-labeled probes. To
distinguish between human or mouse cells, probes spe-
cific to human genomic ALU sequences or to murine
genome repetitive elements Sine/B1 and Sine/B2 were
used, respectively. After hybridization, signals were de-
tected using anti‐DIG alkaline phosphatase‐conjugated
Fab fragments (Roche, Germany) and NBT/BCIP
(Roche, Germany) as substrate.
Statistical analysis
Data are presented as mean values ± standard deviation.
Statistical analysis was performed using SPSS software
(SPSS Inc., Chicago, IL, USA), with application of
Mann-Whitney U test. For comparison of growth curves,
ANOVA test with Bonferroni correction was applied. P
values < 0.05 were referred to as being significant.
Results
Human MSC displayed c-MYC protein accumulation that
was increased upon ex vivo passaging
Due to lack of data available on c-MYC expression in
human MSC, we first examined the c-MYC protein
levels in different types of human mesenchymal cells: ar-
ticular chondrocytes (AC), adipose tissue-derived MSC
(ASC), and bone marrow MSC (BMSC), in comparison
to human cervical cancer cell line HeLa serving here as
a positive control (Fig. 1a). While c-MYC was not de-
tectable in freshly isolated articular chondrocytes, as ex-
pected, MSC from adipose tissue and bone marrow
showed accumulation of c-MYC protein already at pas-
sage 0 (P0), which was further upregulated upon cell
passaging (P1, P2) (Fig. 1a–c). The abundancy of c-MYC
protein in expanded MSC from bone marrow reached
higher levels than in the cervical cancer cell line HeLa
that is known to induce tumors in a mouse xenograft
model [65]. Moreover, MYC protein accumulation
stayed high during expansion at later passages (P5 and
P9), with comparable levels to those detected at passage
1 (Fig. 1c). The MYC protein accumulation dynamic was
in agreement with corresponding data on mRNA expres-
sion (Fig. 1d). Additionally, in the absence of basal fibro-
blast growth factor (bFGF) in the expansion medium,
levels of c-MYC dropped already at passage 5, and even
further at passage 9 (Fig. 1c), indicating that, indeed,
the presence of growth factors in a culture medium
supports c-MYC protein accumulation. Since c-MYC
is known to play an important role in tumorigenesis
as a proto-oncogene, it was important to address next
whether high c-MYC expression could affect prolifera-
tion capacity of the MSC, change their differentiation
characteristics, and induce neoplastic transformation.
C-MYC overexpression in MCS correlated with its
functional activity
To address how c-MYC expression affects MSC, we gen-
erated MSC with constitutively high c-MYC expression.
For this, bone marrow MSC were transduced with retro-
virus containing the expression cassette for human
c-MYC (c-MYC-MSC), and a GFP-expressing retrovirus
was used for obtaining control GFP-MSC. First, we con-
firmed that after transduction, c-MYC-MSC expressed
significantly higher levels of c-MYC mRNA in compari-
son to the control GFP-MSC. Additionally, it remained
higher in later passages in comparison to early passages
(Fig. 2a), and this effect on mRNA expression correlated
with c-MYC protein accumulation (Fig. 2b).
Next, we questioned whether c-MYC protein accumu-
lation due to overexpression also correlated with its
function as a transcription factor and whether c-MYC is
actively recruited to its consensus sequences at genomic
DNA. For this, DNA-binding activity of c-MYC was
assessed by TransAM™ ELISA (enzyme-linked immuno-
sorbent assay) applying an antibody specific for the ac-
tive form of c-MYC when it is bound to its target DNA.
We found that, indeed, elevated c-MYC accumulation in
c-MYC-MSC led to a significant increase in c-MYC oc-
cupancy at its DNA recognition sites in comparison to
the control GFP-MSC (Fig. 2c). Additionally, overexpres-
sion of c-MYC in MSC resulted in elevated expression of
its heterodimer binding partner MAX (Fig. 2d).
Then, we tested how c-MYC overexpression would
affect known MYC antagonists, tumor suppressors
P19ARF and P16INK4A, which can block MYC function.
We found that expression of both P14ARF and
P16INK4A was significantly elevated in c-MYC-MSC,
and it was further increased in later passages by trend
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(Fig. 2e). We conclude that c-MYC overexpression in
MSC resulted in subsequent enhancement of biologic
functions caused by c-MYC, and these effects became
even more pronounced upon ex vivo cell expansion in
later passages. However, the observed upregulation of
tumor suppressor genes in response to c-MYC activation
also suggests that cell safety mechanisms were induced
to counteract these effects, as P16INK4A/P19ARF ex-
pression might prevent a possible neoplastic transform-
ation of MSC by switching on senescence and apoptosis
programs.
C-MYC overexpression promoted proliferation of MSC
For many clinical applications, it is important to achieve
maximal MSC proliferation and provide sufficient
amounts of the cells with multipotent properties. It has
been shown before that the total amount of MYC tran-
scripts in hematopoietic stem cells (HSC) correlates with
the multipotency and self-renewal of these cells [66], so
it might be a plausible idea to use c-MYC overexpression
as an approach to boost MSC proliferation and stemness
properties. The effect of c-MYC on the growth and/or
differentiation of human MSC has not been clarified yet.
Since we found here that the expanded MSC exhibited
higher c-MYC levels upon expansion, we hypothesized
that c-MYC affects proliferation properties of MSC. To
address this question directly, we compared proliferation
rates of c-MYC-MSC in comparison to control GFP-
expressing ones. For this, we recorded growth curves by
counting cell numbers during passages 1 to 15 of MSC
derived from four donors. As expected, c-MYC-MSC
were proliferating significantly faster than control MSC
(GFP-transduced (Fig. 3a) or non-transduced MSC
(Additional file 1: Figure S1)), and their population
doubling number per day was significantly increased
(2.5-fold difference) (Fig. 3b). Of note, there were no sig-
nificant differences between cell proliferation rates be-
tween the two control groups of MSC: GFP and
non-transduced (p = 0.412; data not shown).
To determine whether higher c-MYC expression levels
of some MSC may also confer a selection advantage over
others during expansion, we examined whether the
c-MYC-MSC would overgrow cells with unaltered
c-MYC expression. For this, after passage 4, these two
MSC cell populations were mixed at a following ratio:
80% of GFP-MSC were combined with 20% of
c-MYC-MSC, and the cells were co-cultured together
for another four passages. In control samples, pure GFP-
or c-MYC-MSC cultures were passaged in parallel. It
was found that, although the GFP-MSC population com-
prised a majority in GFP/c-MYC (4:1)-MSC mixed cul-
ture at the start of the experiment, four passages later,
GFP-positive cells were almost lost from co-culture, and
this was not due to loss of the fluorescence signal from
GFP, because it was present in control GFP-only MSC at
the same passage (Fig. 3c, left). This was supported by
A B
C D
Fig. 1 c-MYC protein accumulation that was increased upon ex vivo passaging. a, b Western blot analysis of c-MYC protein abundancies in
different human mesenchymal cell types. Cellular extracts from 25,000 cells for every sample were analyzed by Western blot, with equal volume
loading. a c-MYC was assayed in freshly isolated articular chondrocytes (AC), MSC from adipose tissue (ASC), bone marrow MSC (BMSC), and Hela
cells served as a positive control for c-MYC protein accumulation. b Bone marrow-derived MSC isolated at passages 0 (P0), 1 (P1), and 2 (P2). c, d
c-MYC protein accumulation and mRNA expression were monitored by Western blot (C) and qRT-PCR (n = 3) (d) in BMSC at indicated passages
(P1, P3, P5, P7, P9, P11), in media with or without basic fibroblast growth factor (bFGF), as indicated (c); numbers below WB in C indicate
semi-quantitative evaluation of c-MYC protein abundancies normalized to β-actin, as a fold change to a corresponding P1
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quantitative FACS analysis that exhibited a significant
decline (12-fold difference) of the GFP-positive MSC
population in the co-culture samples within four pas-
sages (Fig. 3c, right). Collectively, these data suggest that
elevated c-MYC expression positively correlated with
proliferation capacity of the MSC, and those with higher
levels for c-MYC were able to overgrow the MSC that
had this gene expression unaffected.
A B
C
E
D
Fig. 2 C-MYC overexpression in MSC correlated with its functional activity. Bone marrow-derived MSC transduced with either c-MYC or GFP
(control) were expanded and collected at passages 2–4 (early passages) or 9–10 (late passages). a, d, e mRNA expression of indicated genes was
measured by qRT-PCR analysis in indicated MSC at early or late passages, as indicated, n = 4; *P < 0.05, versus GFP-MSC at similar passages. b
Western blot analysis of c-MYC protein abundancies in indicated MSC at early or late passages. β-Actin served as a loading control. c c-MYC DNA-
binding activity was measured by ELISA assay in indicated MSC at passage 10 (n = 3) and quantified as the amount of c-MYC (μg/ml) bound to
an oligonucleotide containing a c-MYC consensus sequence; *P < 0.05 versus GFP control
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C-MYC overexpression reduced osteogenic and
adipogenic differentiation of MSC
To find out whether high levels of c-MYC would pro-
mote or, in contrary, prevent differentiation, we sub-
jected MSC, either overexpressing c-MYC or GFP, to
osteogenic, adipogenic, or chondrogenic differentiation
conditions and followed the process by monitoring spe-
cific differentiation markers’ dynamics.
During a 21-day time-course of osteogenic differenti-
ation, c-MYC expression was initially increasing even
higher, and only after day 14 showed a tendency to de-
cline. In control GFP-MSC, levels of c-MYC stayed low
throughout duration of the experiment (with 39-fold dif-
ference to the c-MYC-MSC) (Fig. 4a). Higher levels of
c-MYC during osteogenic differentiation also resulted in
significantly higher levels of total protein content during
osteogenesis, as a reflection of increased proliferation
rates and therefore cell numbers in c-MYC-MSC in
comparison to control GFP-MSC (Fig. 4b). To follow
progression of the osteogenic differentiation and
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Fig. 4 C-MYC overexpression reduced osteogenic and adipogenic markers upon MSC differentiation. a–c c-MYC-MSC or GFP-MSC were expanded
to passage 8, and osteogenic differentiation was induced for 3 weeks (D0–D21). a c-MYC mRNA expression measured by qRT-PCR; n = 2. b Total
protein content monitored with Bradford reagent at day 14. c Calcium deposition measured by Alizarin Red S staining and normalized to total
protein content; d, e C-MYC-MSC or GFP-MSC were expanded to passage 8, and adipogenic differentiation was induced for 3 weeks. d Top:
representative images of MSC stained with Oil Red O; scale bar, 100 μm; bottom: quantitative analysis of Oil Red O content; n = 4; *P < 0.05. b–d
MSC were from n = 4 donors with combined cells at passages 4, 6, 8, and 10; *P < 0.05, versus GFP control at similar time point. e PPARG mRNA
expression measured by qRT-PCR; n = 3, passage 8; *P < 0.05
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monitor calcium deposition, we used Alizarin Red S
staining. We found that, although both groups displayed
successful mineralization, c-MYC-MSC had significantly
reduced Alizarin Red S staining per cell at days 14 and
21 (Fig. 4c). Collectively, these results demonstrate that
osteogenic differentiation in c-MYC-MSC was reduced.
Next, we followed how c-MYC overexpression impacts
adipogenesis, and c-MYC- or GFP-MSC were subjected
to adipogenic culture conditions after passage 8 for
3 weeks. Although both groups successfully accumulated
lipid-containing droplets, c-MYC-MSC had significantly
reduced Oil Red O staining comparing to the control
GFP-MSC (Fig. 4d). Additionally, the expression of
PPARG (peroxisome proliferator-activated receptor
gamma), an important marker for successful adipogene-
sis, was significantly diminished in c-MYC-MSC in rela-
tion to GFP-labeled cells (Fig. 4e). Therefore, these data
suggest that c-MYC decreased not only the osteogenic
but also the adipogenic potential of MSC.
C-MYC overexpression inhibited chondrogenesis and
correlated with increase of hypertrophy
Since we established that c-MYC overexpression influ-
enced both osteogenic and adipogenic lineages of human
MSC, next, it was important to find out how the chon-
drogenic differentiation was affected in our model. The
main problem for the cartilage regeneration therapy with
application of the MSC for joint damage is that the MSC
subjected to chondrogenic differentiation undergo highly
undesirable hypertrophy resulting in induction of type X
collagen, one of the typical markers of endochondral
bone formation. In contrary to MSC, articular chondro-
cytes do not become hypertrophic under the same con-
ditions. They remain collagen type X-negative and can
form stable cartilage tissue in immunodeficient mice,
while samples from chondrogenically differentiated MSC
have been shown to form calcifying grafts [67].
To address how MYC might impact chondrogenesis,
c-MYC- or GFP-MSC were subjected to chondrogenic
differentiation after passage 4. Safranin O staining re-
vealed that, similarly to other lineage progressions,
chondrogenesis was also affected, as less proteoglycans
was deposited in case of c-MYC-MSC in comparison to
control GFP-MSC, and overall, c-MYC-MSC formed
smaller pellets (Fig. 5a). This was supported by the data
on glycosaminoglycan (GAG) deposition that was signifi-
cantly reduced in case of c-MYC-MSC pellets (Fig. 5b).
The same effect was found for DNA content that was
also significantly decreased in pellets formed by these
cells (Fig. 5c). Additionally, it was accompanied with sig-
nificantly diminished mRNA expression levels for the
main chondrogenic transcription factor SOX9 (SRY (sex
determining region Y)-box 9) in c-MYC-MSC in com-
parison to GFP-MSC (Fig. 5d). These data were
supported by the finding that collagen type II expression
(COL2A1) also had a trend to decline (Fig. 5e). In con-
trary to this, the mRNA levels of the hypertrophic
marker, collagen type X (COL10A1), had a tendency to
increase (data not shown). Overall, the ratio between the
two collagens, COL10A1/COL2A1, was significantly
higher in c-MYC-overexpressing chondrocytes (Fig. 5e).
This finding indicates that c-MYC might also contribute
to the onset of hypertrophic differentiation in MSC.
Therefore, all the tested chondrogenic markers uni-
formly indicated that c-MYC overexpression reduced
chondrogenic differentiation of the MSC, similarly as it
was observed for other lineages. Taken together, these
data demonstrate that c-MYC attenuated differentiation
of MSC into all three lineages. Additionally, in case of
chondrogenesis, c-MYC overexpression correlated with
increase of collagen type X in relation to the
chondrogenesis-enhancing collagen type II. This might
also imply a new putative role of c-MYC in promoting a
hypertrophic phenotype.
C-MYC overexpression did not interfere with ectopic bone
formation by human MSC and caused no aberrant effects
in vivo
Would c-MYC overexpression merely result in decrease
of the osteogenic differentiation in vitro or could it abro-
gate bone formation capacity by MSC implants in vivo?
To address this question, as well as follow possible neo-
plastic transformation induced by the transformed MSC,
the regeneration capacity of c-MYC-overexpressing MSC
was assessed in vivo using an ectopic bone formation
mouse model. For this, β-tricalcium phosphate (β-TCP)
scaffolds were used as osteoconductive carrier to form
implants with MSC which were transplanted ectopically
into immunocompromised SCID mice. Most of the
tested constructs displayed successful heterotopic bone
formation 6 weeks later (with exception of two samples
seeded with GFP-MSC from the same donor) (Table 1),
and no phenotypic differences for all tested samples
were found (Fig. 6a). Histomorphometrical analysis of
ectopic bone tissue sections revealed that although the
total area of bone tissue derived from c-MYC-MSC con-
structs in relation to non-transduced control MSC was
significantly reduced (2.5-fold), it was comparable to
control GFP-MSC (Fig. 6b). Species-specific in situ
hybridization confirmed that in every tested MSC group,
de novo bone tissue was derived from human MSC and
not from mouse cells (Fig. 6c and Additional file 1:
Figure S2), thus indicating that c-MYC overexpression
did not abrogate the bone differentiation program in
vivo.
After construct explantation, animals were thoroughly
examined for signs of malignant transformation or
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teratoma growth in their organs and tissues. Macrosco-
pical inspection of liver, lung, spleen, and kidney organs
did not indicate a presence of any abnormalities that
might suggest tumor formation or malignant transform-
ation processes induced by c-MYC-MSC. Additionally,
there was no increase of tissue volume of implants be-
tween the tested groups, as well as no evidence for pres-
ence of malignant cells in all examined multiple tissue
sections. This indicated that higher c-MYC expression
alone would not immediately lead to tumorigenic trans-
formation of the MSC in vivo.
We conclude that, although c-MYC overexpression
promoted higher proliferation rates and altered differen-
tiation properties of MSC, no detrimental effects con-
cerning safety of clinical application of these cells in
terms of tumorigenesis were detected in the experimen-
tal set-up used by this study.
Discussion
Although MSC represent an attractive cell source for
varieties of clinical protocols, their application is
A B
D E
C
Fig. 5 C-MYC overexpression inhibited chondrogenesis and correlated with increase of hypertrophy. C-MYC-MSC or GFP-MSC were expanded to
passage 4, subjected to chondrogenic differentiation for 6 weeks, and induction of chondrogenic markers was evaluated. a Representative
images for Safranin O staining in MSC from two selected donors (n = 4), as indicated; scale bar, 200 μm. b Proteoglycan deposition assessed with
DMMB assay; n = 3. c DNA content quantification done with PicoGreen kit; n = 3. d SOX9 mRNA expression measured by qRT-PCR, in relation to
GFP control; n = 4. e COL2A1 mRNA expression and the ratio of COL10A1 to COL2A1 mRNAs were analyzed by qRT-PCR; n = 4. *P < 0.05
Table 1 Ectopic bone formation in β-TCP/MSC constructs
(positive samples per total number of explants)
Donor MSC GFP-MSC c-MYC-MSC
A 1/1 1/1 1/1
B 2/2 2/2 2/2
C 2/2 1/1 2/2
D 2/2 2/2 2/2
E 2/2 0/2 2/2
Total 9/9 6/8 9/9
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restricted due to limited cell numbers available from a
bone marrow source. Therefore, there is a requirement
for additional expansion of MSC ex vivo before their im-
plantation into a patient. These protocols use culture
media containing a mixture of various growth factors
necessary for maintaining MSC viability, proliferation,
and differentiation potential that also might induce cor-
responding responsive genes, such as MYC. It is known
that MYC contributes significantly to a range of cellular
processes, including proliferation, cell cycle progression,
and pluripotency maintenance in both ES and adults
stem cells. At the same time, MYC is a proto-oncogene,
and its link to the tumorigenic potential of cells has been
established. Thus, MYC plays an ambivalent role as a
proliferation and differentiation factor in stem cells,
as well as an oncogene in cancer cells. Since no data
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on the influence of MYC on bone marrow-derived
MSC were available, it was important to elucidate the
effect of aberrant expression of MYC on MSC in
term of their regenerative properties and safety risks
for clinical applications.
Our initial experiments established that, indeed, in ex-
panded MSC, there were high levels of c-MYC protein
accumulation, and they further increased with the subse-
quent passaging of these cells. Additionally, we found
that high c-MYC protein levels were sufficiently main-
tained only in presence of bFGF in the expansion
medium. This is in agreement with earlier observations
that MYC expression is regulated by FGF signaling [68,
69], as well as with the findings that FGFR1/3 signaling
is essential for the maintenance of proliferation and suc-
cessful chondrogenesis [70]. We hypothesized that
c-MYC expression is important for the establishment
and maintenance of the multipotent stem cell properties of
human MSC. Therefore, lack of MYC or the elimination of
its function would severely impair the potential of these
cells and limit their therapeutic application. On the other
side, excessive MYC levels might block differentiation or
lead to senescence. We found that, indeed, constitutively el-
evated expression of c-MYC in transduced MSC resulted in
a significant increase of their proliferation rates, and
c-MYC overexpression served as a selection marker enab-
ling the transformed MSC to significantly overgrow the
competing control cells in culture. These results were in
agreement with previously shown data on ASC demonstrat-
ing that c-MYC expression correlated with proliferation
capacities of these cells, and a decline in c-MYC expression,
starting at passage 4, reflected in decrease of cell propaga-
tion [32]. However, our study is the first one to demonstrate
that c-MYC expression and proliferative capacity are dir-
ectly linked in MSC, and high c-MYC levels enable to com-
pete and overgrow the cells with low c-MYC.
Remarkably, upon passaging of MSC transduced with
c-MYC, there was a significant upregulation of MYC an-
tagonist genes, P16INK4A and P14ARF, suggesting that a
safety mechanism switch inducing cellular senescence
and preventing neoplastic transformation of MSC was
activated. Similar effects have been demonstrated by an-
other study, where initially high expression of MYC in
ASC, which then attenuated in the later passages, coin-
cided with identical dynamics in the expression pattern
of the CDKN2A gene [32]. This also might suggest that
the ratios between MYC and its antagonists, P14ARF
and P16INK4A, together with an evaluation of the dur-
ation of their upregulation, might reflect the variability
in proliferation capacities between human MSC donors.
If so, these parameters could serve as a functional test to
assess the quality of donor-derived MSC for therapeutic
applications, as those with higher c-MYC levels would
grow better.
Although there have been a few studies describing that
MYC is expressed in MSC during ex vivo expansion,
however, there were no evaluation data how this impacts
the differentiation potential of human MSC. Therefore,
we followed three lineage differentiation processes in
MSC transduced with c-MYC. It was found that the ele-
vated c-MYC expression did not abrogate the differenti-
ation capacity of the MSC, neither in vitro nor in vivo;
however, for all three lineages—osteogenic, adipogenic,
and chondrogenic—the expression of the corresponding
differentiation markers was significantly decreased.
Consequently, a sufficient c-MYC expression seems to
be essential for high proliferation rates and maintenance
of an undifferentiated state of MSC during ex vivo culti-
vation. It implies that in case of low c-MYC expression
or loss of its function, MSC might stop proliferating and
undergoing differentiation. Indeed, it has been demon-
strated earlier in a murine model that elimination of the
functional MYC by expression of a dominant negative
form induced the differentiation of ES cells [71].
Surprisingly, we found that c-MYC overexpression led
to an increased COL10A1/COL2A1 expression ratio, in-
dicating that a balance between these two collagens was
shifted towards hypertrophic collagen type X. This leads
to a conclusion that c-MYC might be involved in the
hypertrophic degeneration process in differentiating
MSC. Our previous epigenetic studies in regulatory gene
regions of type X collagen revealed characteristic DNA
methylation differences between articular chondrocytes
and MSC, which increased in the course of MSC differ-
entiation [72]. We have demonstrated there that all pos-
sible DNA methylation sites in the COL10A1 promoter
were completely methylated in articular chondrocytes
leading to gene silencing, whereas in MSC they
remained demethylated at two E-box putative binding
sites for the transcription factor MYC. It could be that
the increased COL10A1/COL2A1 ratio in the MSC with
high c-MYC expression is directly linked to increased re-
cruitment of c-MYC to the COL10A1 promoter that
drives a formation of the transcriptional activation com-
plex. This might explain mechanistically how accumula-
tion of c-MYC could lead to a shift towards COL10A1
expression in our experiments.
Nevertheless, c-MYC-overexpressing MSC still could
undergo and complete a full osteogenic differentiation
program during in vivo ectopic bone formation exper-
iments and successfully form heterotopic bone in re-
cipient animals, although the total volume of de novo
bone was reduced. This implies that overexpression of
c-MYC does not abrogate the differentiation program
but might affect its correct time-course onset. Indeed,
a recent study has demonstrated that MYC expression
displays an oscillatory pattern which is important for
a correct somite segmentation and elongation during
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embryonic development in mouse [68]. There, it has
been hypothesized that Myc expression levels regulate
and establish a correct timing of WNT and FGF
signaling-regulated gene oscillations involved in the
segmentation clock of a developing mouse embryo.
Our data suggest that a possible attenuation of differ-
entiation observed in vitro may also be found in vivo.
However, there was an indication that in case of
chondrogenesis, a constitutively high c-MYC expres-
sion resulted in increase of the hypertrophic marker
COL10A1. This might suggest that during chondro-
genesis there is a critical checkpoint regulated by a
correct c-MYC expression that defines a switch be-
tween proliferation and differentiation programs. It
would be interesting to investigate further whether
proper timing of different signaling pathways regulat-
ing chondrogenesis is linked to MYC activity.
High proliferation rates of MSC with c-MYC overex-
pression observed in this study, together with a reduced
differentiation onset, manifest an increase of stem
cell-like properties resembled by these cells that may po-
tentiate a risk of tumorigenicity. It is still a matter of
on-going debate between researches whether concerns
about neoplastic transformation induced by MSC, dir-
ectly or via their endocrine activity, have solid evidence
[31]. By experts in the MSC field, it has been recom-
mended to keep PDN (population doubling number) low
to reduce a risk of karyotype changes, although no direct
evidence has been provided yet whether ex vivo passa-
ging causes chromosomal aberrations [3, 18].
In this context, we interrogated this question directly
and tested the c-MYC-overexpressing MSC in vivo to as-
sess whether an increase in stemness and high PDN
characteristics observed in these cells would result in
tumor growth incidence. Despite of high proliferative
potential, differentiation capacity and elevated c-MYC
expression, the MSC used for implantation into immu-
nodeficient mice did not form any tumors in vivo. No
other indications for malignant growth or teratomas
(non-malignant tumor-like formations) were observed in
our tests.
Different studies on a role of c-MYC in malignant
transformation suggest that high expression of MYC
alone is not sufficient to induce malignant transform-
ation, and only when MYC gene amplification is com-
bined with other oncogenes overexpression, e.g., Her2
[49], or with a loss of tumor suppressors, either due
to deletion, e.g., CDKN2A [50], or loss-of-function,
e.g., RB protein [51], this leads to dramatic boost in
neoplastic cell growth. Our finding that overexpres-
sion of c-MYC correlated with P16INK4A and
P14ARF expression suggests that, in case of an ab-
sence of the concomitant mutations of other onco-
genes and/or tumor suppressors, cells are able to
counteract activating functions of c-MYC and induce
safety mechanisms. These factors also need to be
taken into account during MSC assessment in terms
of safety and quality controls of donor material before
clinical applications. Additionally, longer observation
times need to be included.
Our results are in agreement with many previous
reports demonstrating that human MSC and ASC do
not cause malignant growth [21–25, 32]. Therefore, in
contrary to induced pluripotent stem cells (iPS) cells
that are known to induce multiple teratoma growth
[73, 74], in case of human MSC, so far, there is not
enough evidence to suggest that application of exten-
sively expanded MSC populations which might be
enriched in c-MYC-overexpressing cells should be
hindered by increased tumorigenesis risk. Our data
are in line with general conclusions made by the Cell
Products Working Party and the Committee for Ad-
vanced Therapies elucidating the risk of potential
tumorigenicity related to MSC-based therapies [31]
agreeing on a conclusion that in current animal
models, in which human MSC are used, no direct
evidence has been observed to date that would sug-
gest induced tumor formation. As a final remark, it is
important to note that this study does not imply that
forced c-MYC overexpression might be assumed as a
probable strategy to boost the proliferation character-
istics of MCS for clinical applications. Our data dem-
onstrated that the constituently high expression of
c-MYC not only resulted in good proliferation rates
of the MSC but also caused a detrimental shift to-
wards a hypertrophic collagen phenotype and cartilage
degeneration during chondrogenesis. In addition, to
prevent uncontrolled cell proliferation and potential
malignant transformation, the intact function of
tumor suppressor genes P14ARF/P16IK4A regulating
apoptosis and senescence would be absolutely essen-
tial in selected MSC donors. These two issues point
to lack of safety in elevating c-MYC protein levels for
therapeutic applications.
Conclusions
This study demonstrates for the first time that the prolif-
eration capacity of human bone marrow MSC is linked
to c-MYC expression and suggests a novel putative role
of c-MYC in promoting a hypertrophic phenotype dur-
ing chondrogenesis. Although further investigations
might be necessary to assess the risk of tumorigenic
transformation that could be caused by application of
the MSC undergoing long-term ex vivo expansion, our
data suggest that elevated expression of c-MYC alone
did not immediately lead to tumor formation in the
tested in vivo mouse model.
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Additional file
Additional file 1 Figure S1. C-MYC overexpression promoted proliferation
of MSC. Cell proliferation kinetics were assessed by recording cumulative cell
numbers in the same-donor MSC, either control non-transduced or c-MYC-
transduced, at every passage during expansion (passages 1 to 15); n= 3;
*P< 0.05 (ANOVA test). Figure S2. Human ALU and murine Sine probes used
for in situ hybridization provide species-specific staining in corresponding
bone tissues. In situ hybridization analysis using either mouse or human bone
tissue as corresponding positive and negative species controls with probes
specific to human genomic ALU sequences or to murine genome repetitive
elements Sine, to demonstrate the absence of cross-reactivity; scale bar, 50 μm.
Table S1. List of qRT-PCR primers used in this study. (PDF 341 kb)
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